Goldline Pharmaceutical IPO
Price Band
₹41 – ₹43
Issue Size
₹11.61 Cr
Lot Size
3000 shares
Min ₹1,29,000
Issue Dates
12 May – 14 May 2026
Listing Date
19 May 2026
About Goldline Pharmaceutical Ltd
Goldline Pharmaceutical Ltd. is engaged in the business of marketing pharmaceutical products under the “Goldline” brand. The company offers products across multiple therapeutic segments including physician care, cardiology, diabetology, pediatrics, critical care, orthopedics, gastroenterology, neurology, urology, and supportive cancer care. The company operates through an asset-light business model and does not manufacture medicines directly. It partners with third-party manufacturers for product manufacturing based on its specifications and market research. Products are distributed through a network of distributors, retailers, wholesalers, hospitals, and healthcare providers across states including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Visit WebsiteIPO Details
| Price Band | ₹41 – ₹43 |
| Face Value | ₹10 |
| Lot Size | 3000 shares(Min ₹1,29,000) |
| Issue Size | ₹11.61 Cr |
| Fresh Issue | ₹11.61 Cr |
| Total Shares Offered | 27,00,000 |
Objects of the Issue
Prepayment or repayment of certain outstanding borrowings availed by the company and general corporate purposes.
Key Financial Metrics
EPS (Basic)
₹3.09
P/E Ratio
13.93x
ROE
21.02%
ROCE
24.22%
Debt / Equity
1.07
Financial Performance
| Particulars (₹ Cr) | FY23 | FY24 | FY25 | 9M FY25 |
|---|---|---|---|---|
| Revenue | 19.85 | 23.57 | 28.06 | 21.41 |
| EBITDA | 2.19 | 4.3 | 5.83 | 4.16 |
| PAT | 0.26 | 1.81 | 2.83 | 2.22 |
| Total Assets | 19.39 | 22.93 | 26.28 | 27.4 |
| Net Worth | 5.89 | 7.86 | 10.35 | 12.36 |
| Total Borrowings | 10.83 | 11.13 | 11.03 | 9.47 |
Valuation
Market Capitalisation
P/E Ratio
Promoter Holding
Public Holding
Lot Size & Allocation
Investment by Category
| Category | Lot Size | Min Investment | Max Investment |
|---|---|---|---|
| Retail (RII) | 2 × 3000 | ₹1,29,000 | ₹2,58,000 |
Reservation / Allocation
| Category | Allocation | Cut-off |
|---|---|---|
| QIB (Qualified Institutional Buyers) | 49.65% | Yes |
| NII (Non-Institutional Investors) | 15.22% | No |
| RII (Retail Individual Investors) | 35.13% | Yes |
Registrar & Lead Managers
Registrar
Lead Managers (1)
Anchor Investors
| # | Investor | Type | Shares | Amount (₹ Cr) | % of Issue |
|---|---|---|---|---|---|
| 1 | Anchor Investor Pool | FII | 7,32,000 | 3.15 | 27.11% |
Peer Comparison
| Company | Listed | Mkt Cap (₹ Cr) | EPS (₹) | P/E | ROE % |
|---|---|---|---|---|---|
| Goldline Pharmaceutical IPO (this IPO) | — | 52.89 | ₹3.09 | 13.93x | 21.02% |
| Cipla Ltd | Yes | 11,20,000 | ₹35.4 | 28.1x | 16.8% |
| Sun Pharmaceutical Industries Ltd | Yes | 38,00,000 | ₹42.15 | 32.5x | 18.2% |
| Dr. Reddy's Laboratories Ltd | Yes | 9,50,000 | ₹48.6 | 26.4x | 15.9% |
| Lupin Ltd | Yes | 10,50,000 | ₹32.75 | 30.1x | 14.5% |
Data as of 31/3/2025
Frequently Asked Questions
12 questions about Goldline Pharmaceutical IPO IPO
Important Dates
Community Discussion
Ask questions and share your thoughts about this IPO
Be the first to ask or share about Goldline Pharmaceutical IPO